Company Profile

Satori Pharmaceuticals Inc
Profile last edited on: 5/7/19      CAGE: 4BRM7      UEI:

Business Identifier: Gamma-secretase modulators: inhibiting amyloid beta 42 plaque component in Alzheimer’s diseas
Year Founded
2004
First Award
2005
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

281 Albany Street
Cambridge, MA 02139
   (617) 547-0022
   mark.findeis@satoripharma.com
   www.satoripharma.com
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Having been working in the neurodegeneration space, in May 2013, Satori Pharmaceuticals, Inc. Ceased operations. The firm had operated as a biopharmaceutical company developing new kinds of drugs to treat protein misfolding diseases, including Alzheimer's disease and Parkinson's disease, and type 2 diabetes. The company had also developed a portfolio of preclinical programs that provide a drug development pipeline

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $100,000
Project Title: Beta-amyloid 1-42 lowering agent for Alzheimer's Disease
2005 1 NIH $100,000
Project Title: NC/OFQ analogs as ORL1 agonists to promote gut motility

Key People / Management

  Jeffrey Ives -- CEO

  Mark A Findeis -- Scientific Advisor and Scientific Co-founder